Beyond the scale: what GLP-1s do for your heart, kidneys, and sleep apnea

Most coverage of GLP-1s focuses on the number on the scale, but three of the largest, most rigorously designed trials in the drug class weren't primarily about weight loss at all — they tested whether semaglutide and tirzepatide reduce heart attacks, slow kidney disease, and treat sleep apnea. All three read out with genuinely significant results, and all three now have FDA-approved labeling reflecting them.

The heart: the SELECT trial

SELECT enrolled over 17,600 adults with established cardiovascular disease and overweight or obesity, but without diabetes, and randomized them to semaglutide 2.4 mg or placebo, tracking major adverse cardiovascular events — heart attack, stroke, or cardiovascular death — as the primary outcome¹. Semaglutide reduced the rate of these events by a statistically significant margin compared to placebo, and the effect emerged well before most of the weight loss occurred, suggesting a genuine cardiovascular benefit beyond what weight reduction alone would explain. This trial is the basis for semaglutide's added cardiovascular-risk-reduction indication, which is also why it can matter for coverage — our GLP-1 insurance coverage guide covers how that added label has opened Medicare access for some patients who wouldn't otherwise qualify under an obesity-only indication.

The kidneys: the FLOW trial

FLOW enrolled adults with type 2 diabetes and chronic kidney disease and tested whether semaglutide could slow kidney function decline, tracking a composite outcome of major kidney disease events, sustained kidney function decline, and kidney or cardiovascular death². The trial was stopped early by its independent monitoring committee — a sign the treatment effect was strong enough that continuing to randomize patients to placebo was no longer considered appropriate — after semaglutide showed a clear reduction in the composite kidney outcome. A related analysis of SELECT's own data found meaningful long-term kidney benefits in that cardiovascular trial's population too, reinforcing that the kidney-protective signal shows up across more than one large trial³.

Sleep apnea: the SURMOUNT-OSA trial

SURMOUNT-OSA specifically tested tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea, measuring the apnea-hypopnea index (AHI) — the standard measure of how often breathing is disrupted during sleep — as the primary outcome⁴. Tirzepatide produced substantial reductions in AHI compared to placebo, with a meaningful share of participants seeing their sleep apnea severity category improve. This is the trial behind tirzepatide's added sleep apnea indication, and it's directly relevant to insurance coverage too, since sleep apnea is one of the comorbidities that can qualify a patient for coverage under a lower BMI threshold — again, see our insurance coverage guide for how that works in practice.

Why these results matter beyond the numbers

All three trials share a structural strength: they're large, randomized, placebo-controlled, and designed around a hard clinical outcome (a heart attack, a kidney failure event, a validated sleep study measure) rather than a surrogate marker like weight alone. That's a meaningfully higher evidence bar than most claims made about GLP-1s, and it's part of why these three trials specifically anchor the FDA's expanded, non-weight-loss indications for the drug class. If you're comparing semaglutide and tirzepatide more broadly, semaglutide vs. tirzepatide: what the trials actually show covers how their core weight-loss and diabetes trial data compares.

The honest bottom line

SELECT, FLOW, and SURMOUNT-OSA are three of the most rigorous trials run on this drug class, and each found a real, clinically meaningful benefit beyond weight loss — reduced cardiovascular events, slowed kidney disease progression, and reduced sleep apnea severity, respectively. None of that changes the drugs' known side-effect profile or makes them appropriate for everyone, but it's a genuinely different evidence category than the weight-loss headlines usually convey. This is educational information about clinical trial findings, not medical advice — whether any of these benefits are relevant to your own care is a conversation for your prescriber.